Moleculin Biotech granted Australian patent for Annamycin to 2040

Moleculin Biotech, Inc. (MBRX) announced a new patent grant in Australia.

Rhea-AI Filing Summary

Moleculin Biotech, Inc. (MBRX) announced a new patent grant in Australia. The company reported that IP Australia has granted Patent No. 2024203598 titled “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE,” covering certain preliposomal Annamycin lyophilizates with improved stability and high purity.

The patent’s base term currently extends until June 2040, with potential extension to account for time required to fulfill regulatory approval requirements. The company furnished a press release with further details as an exhibit.

Insights

Biotech IP analyst

Australian patent strengthens Annamycin formulation protection; neutral near-term impact.

Moleculin Biotech disclosed that IP Australia granted Patent No. 2024203598 for preliposomal Annamycin lyophilizates, addressing stability and purity. Stronger intellectual property can help protect formulation know-how and support future commercialization steps.

The base patent term extends to June 2040, with potential extension tied to regulatory approval timelines. While this enhances the IP position, it does not alter near‑term finances or approvals; practical impact depends on subsequent clinical and regulatory progress disclosed elsewhere.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Moleculin Biotech (MBRX) announce in its 8-K?

The company announced IP Australia granted Patent No. 2024203598 for “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.”

What does the new Australian patent cover for MBRX?

It covers certain preliposomal Annamycin lyophilizates with improved stability and high purity.

How long does Moleculin’s Australian patent last?

The base patent term currently extends until June 2040, subject to extension for time required to fulfill regulatory approval requirements.

Which product area is addressed by this MBRX patent?

The patent relates to Annamycin, specifically preliposomal lyophilizate formulations.

How was the information about the MBRX patent disclosed?

It was furnished via a press release attached as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/29/2025 - 08:35 AM Learn about SEC filing dates

false 0001659617 0001659617 2025-10-29 2025-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 29, 2025

MOLECULIN BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-37758	47-4671997
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

5300 Memorial Drive, Suite 950, Houston, TX 77007

(Address of principal executive offices and zip code)

(713) 300-5160

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).          Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Common Stock, par value $.001 per share	MBRX	The NASDAQ Stock Market LLC

Item 7.01 Regulation FD Disclosure

On October 29, 2025, Moleculin Biotech, Inc. (the “Company”), issued a press release which announced that the Australian Patent Office (IP Australia) has granted Patent No. 2024203598 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE,” with claims covering certain preliposomal Annamycin lyophilizates with improved stability and high purity, with a base patent term currently extending until June 2040, subject to extension to account for time required to fulfill requirements for regulatory approval.

A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1	Press Releasedated October 29, 2025
104	Cover page Interactive Data File (formatted as Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOLECULIN BIOTECH, INC.
	Date:	October 29, 2025
	By:	/s/ Jonathan P. Foster
		Jonathan P. Foster